Chat with us, powered by LiveChat

Loading...

High Potency Active Pharmaceutical Ingredients (HPAPI) Market Report

RA00364

High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Product (Synthetic, Biotech), Application (Oncology, Hormonal, Glaucoma, Others), End-User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Healthcare): Global Opportunity Analysis and Industry Forecast, 2020–2027

RA00364

Pages: 120

Jun 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on High Potency Active Pharmaceutical Ingredients (HPAPI) Market

The global high potency active pharmaceutical ingredients (HPAPI) market is estimated to witness growth due to the growing demand for outsourcing of these intermediates and the development of the oncology market, which pushes the production of HPAPI.

High Potency Active Pharmaceutical Ingredients (HPAPI) Market, Analysis:

High-potency pharmaceutical active ingredients (HPAPIs) are a significant field of the pharmaceutical manufacturing industry. The HPAPI market includes a variety of product types, such as oncology-focused medicines, across various clinical fields. Although the largest proportion of HPAPIs is used to formulate anti-cancer medications. Several advances, such as packaging, control techniques, and growing investments, are encouraging the market’s growth.

Increasing inclination to outsource HPAPI production is expected to drive the global high-potency pharmaceutical active ingredients (HPAPIs) market:

Outsourcing has proved to be the most viable choice for HPAPI production with the development of a favorable regulatory framework. Outsourcing enables major drug producers to concentrate on brand development and product releases, maintenance of the production cycle, and other operations. Thus, increasing inclination to outsource HPAPI production is anticipated to drive the market growth.

The complex HPAPI production process is anticipated to restrain the growth of global high-potency pharmaceutical active ingredients (HPAPIs) market:

Producing HPAPIs is a complex procedure. The main obstacles include eliminating cross-contamination through processing, protecting plant workers, and everybody in the supply chain who produce the finished drug product. The major challenge will be to decide the correct containment and safety policy, including facility construction, containment devices, protocols, and personal protective equipment (PPE). Thus, these factors are anticipated to bring a decline in the global high-potency pharmaceutical active ingredients (HPAPIs) market.

Rising demand for oncology drugs to create enormous opportunities for the global high-potency pharmaceutical active ingredients (HPAPIs) market:

HPAPIs have the potential to target specific cancer cells and are used for extremely effective medication formulations like oncology drugs. According to the World Health Organization, worldwide cancer rates are expected to increase by 2020; within 17 years, the figure will increase to 20 million, the study states. This rise in the number of cancer cases has a major effect on the global sales of drugs and treatments. Therefore, rising demand for oncology drugs is anticipated to create a wide scope of opportunities in the global HPAPIs market.

High-Potency Pharmaceutical Active Ingredients (HPAPIs) Market, by Product:

Synthetic will be most lucrative till 2027

By product, the global HPAPIs market is divided into synthetic and biotech. Amongst these, the synthetic product is expected to dominate the market shares because of easier methods for utilizing synthesis molecules combined with greater raw material quality. Moreover, in the foreseeable period, several modified medicines made of synthetic HPAPI are expected to go off patent.

High-Potency Pharmaceutical Active Ingredients (HPAPIs) Market, by Applications:

Oncology is estimated to dominate the market in the upcoming period

By applications, the global HPAPIs market is classified into oncology, hormonal, glaucoma, and others. Out of these, oncology is anticipated to lead the market shares due to rising cancer patients globally. Oncology components are commonly used in the form of antibody-drug conjugates (ADCs), which is an innovative and significant discovery for treating cancer.

High-Potency Pharmaceutical Active Ingredients (HPAPIs) Market, by End-Users:

Healthcare is estimated to be the highest growing till 2027

By end-users, the global HPAPIs market is bifurcated into academic & research institutes, pharmaceutical & biotechnology companies, and healthcare. Amongst these, the healthcare sector is expected to dominate the market shares due to the rising obese population and increasing usage of HPAPIs in medicines and treatments.

High-Potency Pharmaceutical Active Ingredients (HPAPIs) Market, by Region:

Asia-Pacific region will have lucrative opportunities for the market investors

The global HPAPIs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominates the market share due to rising patients with chronic illness combined with growing competition for fast-acting medications and improved effectiveness. Asia-Pacific is anticipated to be the fastest-growing region due to the prosperous market for generic drugs, the growing development of healthcare infrastructures, and the presence of growth opportunities in the untapped markets.

Key Participants in the Global HPAPIs Market:

Merger & acquisition and advanced product development are the frequent strategies followed by the market players

Key participants in the Global HPAPIs Market

Source: Research Dive Analysis

Some of the significant global HPAPIs market players are Pfizer Inc., Novartis International AG, Sanofi S.A, C.H. Boehringer Sohn AG & Ko. KG, Bristol Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., Merck & Co. Inc.,  AbbVie, Mylan N.V., and others.

To reach into local markets, market players favor inorganic development strategies. The major players in the HPAPIs are placing more emphasis on merger & acquisition and innovative technology growth. These are the regular techniques that the existing organizations pursue. To focus more on market player's competition research, the study discusses Porter's five forces model.

Aspect

Particulars

 Historical Market Estimations

 2018-2019

 Base Year for Market Estimation

 2019

  Forecast timeline for Market Projection

 2020-2027

 Geographical Scope

 North America, Europe, Asia-Pacific, LAMEA

 Segmentation by Product

  • Synthetic
  • Biotech

 Segmentation by Applications

  • Oncology
  • Hormonal
  • Glaucoma
  • Others

 Segmentation by End-Users

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Healthcare

 Key Countries Covered

U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia

 Key Companies Profiled

  • Pfizer Inc.
  • Novartis International AG
  • Sanofi S.A
  • C.H. Boehringer Sohn AG & Ko. KG
  • Bristol Myers Squibb Co.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Co.
  • Merck & Co. Inc.
  • AbbVie
  • Mylan N.V.

FREQUENTLY ASKED QUESTIONS?
 

A. Pfizer Inc., Novartis International AG, and Sanofi S.A are some of the key players in the global HPAPIs market.

A. The Asia-Pacific region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Technological advancements, product development, along with joint ventures, are the key strategies opted by the operating companies in this market.

A. Eli Lilly and Co., Merck & Co. Inc., and AbbVie are the companies investing more in R&D activities for developing new products and technologies.

Research Methodology

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed